ANL
Adlai Nortye Ltd.
NASDAQ · Healthcare · Biotechnology · KY
$15.01
+1.76%Aug 3, 2026, 11:00 UTC
Adlai Nortye announced that it has submitted a clinical trial notification and received HREC approval to start a Phase I clinical trial of its pan-RAS(ON) inhibitor ADC AN4035 in Australia.
Source: